Anti-platelet drugs and outcome in severe infection: Clinical impact and underlying mechanisms
- 1 January 2009
- journal article
- Published by Informa UK Limited in Platelets
- Vol. 20 (1), 50-57
- https://doi.org/10.1080/09537100802503368
Abstract
Platelet activation contributes to microvascular thrombosis and organ failure in systemic inflammation. We tested the hypothesis whether anti-platelet drugs might favourably affect outcome in patients at risk for organ failure as well as in a mouse model of endotoxin shock. Two hundred twenty-four consecutive patients who were admitted for community acquired pneumonia over a time period of 5 years to a University Hospital were enrolled; about 20% of whom received anti-platelet drugs (acetylsalicylic acid, thienopyridines) for secondary prevention of cardiovascular disease. Patients with anti-platelet drugs were about 12 years old but did not differ in SOFA score and routine laboratory parameters at admission. Logistic regression and 2 x 2 table analysis in age-matched subgroups indicated that anti-platelet drugs may reduce the need of intensive care treatment (odds ratio (OR) 0.32 [95% confidential interval: 0.10-1.00] and 0.19 [0.04-0.87], respectively). In age-matched subgroups, the use of anti-platelet drugs was also associated with a shorter stay in hospital (13.9 +/- 6.2 vs. 18.2 +/- 10.2 days; p < 0.02). In the animal model Balb/c mice were pre-treated with clopidogrel (added to drinking water) for 4 days prior to intraperitoneal (i.p.) administration of endotoxin (lipopolsaccharide (LPS) from Escherichia coli 0111:B4). Within the first 48 hours after LPS there were no differences between clopidogrel and control animals (n = 26 each) in macro-haemodynamics. However, clopidogrel abolished the LPS-induced drop in platelet count and reduced fibrin deposition in lung tissue. Using DNA microarray technology, we could show that clopidogrel suppressed endotoxin-induced up-regulation of inflammation-relevant genes, including arachidonate-5-lipoxygenase activating protein and leukotriene B4 receptor 1. According to our data a possible benefit of anti-platelet drugs in patients on risk for systemic inflammation and organ failure should be tested in a prospective trial.Keywords
This publication has 47 references indexed in Scilit:
- Human endothelial impairment in sepsisAtherosclerosis, 2008
- Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits modelAtherosclerosis, 2007
- The role of platelet CD154 in the modulation in adaptive immunity.Immunologic Research, 2007
- Platelets as Mediators of InflammationHematology/Oncology Clinics of North America, 2007
- Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumoniaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2006
- New Roles for an Old Drug: Inhibition of Gene Expression by Dipyridamole in Platelet–Leukocyte AggregatesTrends in Cardiovascular Medicine, 2006
- Anti-inflammatory effects of clopidogrel intake in renal transplant patients: Effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkersClinical Pharmacology & Therapeutics, 2005
- Platelets: signaling cells in the immune continuumTrends in Immunology, 2004
- Serial Evaluation of the SOFA Score to Predict Outcome in Critically Ill PatientsJAMA, 2001
- Impairment of forearm vasodilatation to acetylcholine in hypercholesterolemia is reversed by aspirin.Cardiovascular Research, 1998